<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159967" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tadalafil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fahmy</surname>
            <given-names>George</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hess</surname>
            <given-names>Jaclyn</given-names>
          </name>
          <aff>St. John's University &#x00026; Long Island University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>George Fahmy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaclyn Hess declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159967.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Tadalafil is classified as an oral phosphodiesterase type 5 (PDE5) inhibitor. Tadalafil was approved by the US Food and Drug Administration (FDA) in 2003 and is primarily used as first-line therapy for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH).<xref ref-type="bibr" rid="article-159967.r1">[1]</xref><xref ref-type="bibr" rid="article-159967.r2">[2]</xref> Tadalafil&#x000a0;acts by relaxing the muscles in the bladder and prostate and by increasing blood flow to the penis during sexual stimulation.<xref ref-type="bibr" rid="article-159967.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Erectile Dysfunction (ED): Tadalafil is widely used for treating ED&#x000a0;and is effective in enhancing erectile function.<xref ref-type="bibr" rid="article-159967.r4">[4]</xref></p>
        <p>Benign Prostatic Hyperplasia (BPH): Tadalafil is indicated for treating&#x000a0;the signs and symptoms of BPH.<xref ref-type="bibr" rid="article-159967.r5">[5]</xref>&#x000a0;</p>
        <p>ED and BPH: Tadalafil can be used when both conditions coexist.<xref ref-type="bibr" rid="article-159967.r6">[6]</xref></p>
        <p>Pulmonary Arterial Hypertension (PAH):&#x000a0;For effective treatment of PAH, tadalafil is one of the drugs of choice.<xref ref-type="bibr" rid="article-159967.r7">[7]</xref> In treatment-naive pulmonary arterial hypertension patients classified as WHO Functional Class II and III, the American College of Chest Physicians suggests initiating combination therapy with ambrisentan and tadalafil for the improvement of 6-minute walk distance (6MWD).<xref ref-type="bibr" rid="article-159967.r8">[8]</xref>&#x000a0;</p>
        <p>
<bold>Off-Labeled Uses</bold>
</p>
        <p>Lower Urinary Tract Symptoms (LUTS): Tadalafil may be beneficial in managing LUTS associated with BPH.<xref ref-type="bibr" rid="article-159967.r9">[9]</xref></p>
        <p>Raynaud's Phenomenon: Some evidence suggests&#x000a0;tadalafil's&#x000a0;effectiveness in managing this condition.<xref ref-type="bibr" rid="article-159967.r10">[10]</xref></p>
        <p>High-Altitude Pulmonary Edema (HAPE) Prevention: Tadalafil is used off-label for&#x000a0;preventing&#x000a0;HAPE, which is more common in individuals ascending rapidly to altitudes greater than 2500-3000 meters.<xref ref-type="bibr" rid="article-159967.r11">[11]</xref><xref ref-type="bibr" rid="article-159967.r12">[12]</xref><xref ref-type="bibr" rid="article-159967.r11">[11]</xref></p>
      </sec>
      <sec id="article-159967.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tadalafil functions as a selective inhibitor of phosphodiesterase type 5 (PDE5), an enzyme prominently found in the smooth muscle cells of the corpus cavernosum in the penis, as well as in the pulmonary vasculature and the prostate. PDE5 breaks down cyclic guanosine monophosphate (cGMP), a crucial molecule in the vasodilatory process. By inhibiting PDE5, tadalafil prevents the degradation of cGMP, thereby enhancing and prolonging its effects.</p>
        <p>Cyclic guanosine monophosphate plays a vital&#x000a0;role in the physiological process of erection. It is synthesized in response to nitric oxide (NO) release during sexual stimulation. NO activates guanylate cyclase, which converts guanosine triphosphate (GTP) into cGMP. Increased levels of cGMP lead to the relaxation of smooth muscle cells in the corpus cavernosum and dilation of blood vessels, which facilitates an increased blood flow into the penile tissue, resulting in an erection.<xref ref-type="bibr" rid="article-159967.r13">[13]</xref></p>
        <p>In addition to its effects on the corpus cavernosum, tadalafil's inhibition of PDE5 in the pulmonary vasculature leads to vasodilation, reducing pulmonary arterial pressure. This makes tadalafil effective in treating pulmonary arterial hypertension (PAH). The drug's mechanism in the prostate and bladder helps alleviate benign prostatic hyperplasia (BPH) symptoms by relaxing these tissues and improving urinary flow.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption:&#x000a0;Tadalafil is readily absorbed following oral administration. Its bioavailability is not significantly influenced by food, allowing for flexible dosing. Peak plasma concentrations (Cmax) are typically achieved within 2 hours (Tmax) post-dose, indicating a quick onset of action.<xref ref-type="bibr" rid="article-159967.r14">[14]</xref>&#x000a0;As a lipophilic molecule, tadalafil has good membrane permeability, contributing to its efficient absorption.&#x000a0;</p>
        <p>Distribution:&#x000a0;Tadalafil is widely distributed throughout the body. Its volume of distribution suggests extensive tissue uptake and distribution. Ninety-four percent of tadalafil in the plasma is bound to&#x000a0;proteins like albumin and &#x003b1;-1 acid glycoprotein. This high degree of protein binding limits the free fraction of the drug in circulation but facilitates its extended duration of action.<xref ref-type="bibr" rid="article-159967.r15">[15]</xref></p>
        <p>Metabolism:&#x000a0;Metabolized predominantly in the liver, tadalafil undergoes biotransformation mainly through the cytochrome P450 (CYP) 3A4 isoenzyme.&#x000a0;The major metabolite is methyl-catechol glucuronide, which is much less potent than the parent compound. This metabolite and additional minor metabolites indicate the involvement of conjugation reactions in tadalafil's metabolism.<xref ref-type="bibr" rid="article-159967.r16">[16]</xref></p>
        <p>Elimination:&#x000a0;Tadalafil and its metabolites are primarily excreted via the fecal route (approximately 61%), with renal excretion accounting for about 36% of the drug elimination.&#x000a0;The drug has a prolonged terminal half-life (approximately 17.5 hours), which supports its long duration of action. This pharmacokinetic property makes tadalafil suitable for once-daily dosing in chronic conditions.<xref ref-type="bibr" rid="article-159967.r17">[17]</xref></p>
      </sec>
      <sec id="article-159967.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Tadalafil is an oral tablet with strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. The FDA has also approved a combination oral capsule containing finasteride and tadalafil for BPH.<xref ref-type="bibr" rid="article-159967.r18">[18]</xref>&#x000a0;The capsule contains 5mg finasteride and 5mg tadalafil.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The recommended adult doses differ based on the condition being treated. For erectile dysfunction in the adult population, tadalafil can be administered as needed at an initial dose of 10 mg at least 30 minutes before sexual activity, or it can be administered daily at a dose of 2.5 to 5mg, irrespective of sexual activity. Depending on tolerability and efficacy, dosing can be adjusted to either 5 mg or 20 mg.<xref ref-type="bibr" rid="article-159967.r19">[19]</xref>&#x000a0;In benign prostatic hyperplasia (BPH), the advised dosage is 5 mg once daily.<xref ref-type="bibr" rid="article-159967.r20">[20]</xref>&#x000a0;When using combination finasteride and tadalafil, a fixed-dose combination of&#x000a0;finasteride 5 mg and tadalafil 5 mg is administered orally once daily without food for up to 26 weeks for benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-159967.r21">[21]</xref>&#x000a0;The usual tadalafil dosage for pulmonary arterial hypertension (PAH) is 40 mg daily. However, this can be initiated at 20 mg daily and increased after 4 weeks.<xref ref-type="bibr" rid="article-159967.r22">[22]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Caution is advised when using tadalafil for hepatic impairment. The maximum recommended dose in cases of mild to moderate hepatic impairment is 10 mg, and its use is not recommended in severe hepatic impairment.<xref ref-type="bibr" rid="article-159967.r23">[23]</xref></p>
        <p><bold>Renal impairment:</bold> In patients with renal impairment, no dose adjustment of tadalafil is needed for mild to moderate cases, but the maximum recommended dose for severe impairment, when creatinine clearance is less than 30 mL/min, is 10 mg.<xref ref-type="bibr" rid="article-159967.r24">[24]</xref>&#x000a0;</p>
        <p><bold>Pregnancy considerations:</bold> Tadalafil is not recommended during pregnancy due to insufficient safety data when treated for PAH, LUTS, or HAPE prevention.<xref ref-type="bibr" rid="article-159967.r25">[25]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> As for breastfeeding, it is unknown if tadalafil is excreted in human milk, so caution is advised.<xref ref-type="bibr" rid="article-159967.r26">[26]</xref></p>
        <p><bold>Pediatric patients:</bold> The safety and efficacy of tadalafil in pediatric patients have not been established, therefore it is not recommended for treatment within the pediatric population.<xref ref-type="bibr" rid="article-159967.r27">[27]</xref></p>
        <p><bold>Older patients:</bold> No specific dose adjustment is needed for geriatric patients based on age alone; a cautious approach is recommended due to potential increased sensitivity in some older individuals.<xref ref-type="bibr" rid="article-159967.r28">[28]</xref></p>
      </sec>
      <sec id="article-159967.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Effects</bold>
</p>
        <p>Headache: This adverse effect is the most commonly reported side effect, likely due to tadalafil's vasodilatory impact on cerebral blood vessels. Headaches induced by tadalafil range from mild to severe and are generally transient.<xref ref-type="bibr" rid="article-159967.r29">[29]</xref></p>
        <p>Dyspepsia: Dyspepsia is a frequent reaction characterized by indigestion, heartburn, and abdominal discomfort. Tadalafil's relaxation effect on gastrointestinal smooth muscles is thought to contribute to these symptoms.<xref ref-type="bibr" rid="article-159967.r30">[30]</xref></p>
        <p>Back Pain and Myalgia: Many users report musculoskeletal discomfort, particularly in the back and muscles. While the exact mechanism is unclear, it is thought to be related to the effects of tadalafil on smooth muscle tissue.</p>
        <p>
<bold>Severe Adverse Effects and Potential Injuries</bold>
</p>
        <p>Nasal Congestion: Nasal congestion occurs due to the dilation of blood vessels in the nasal passages.<xref ref-type="bibr" rid="article-159967.r31">[31]</xref></p>
        <p>Hypotension: Vasodilation of vascular smooth muscle can lead to modest reductions in blood pressure of about 7 mm Hg in systolic and 5 mm Hg in diastolic pressure, and this effect can last up to 12 hours.<xref ref-type="bibr" rid="article-159967.r32">[32]</xref></p>
        <p>Flushing: Characterized by redness of the face, neck, or chest, this reaction results from vasodilation.<xref ref-type="bibr" rid="article-159967.r33">[33]</xref></p>
        <p>Limb Pain: Pain in the arms or legs is less common but can cause discomfort.<xref ref-type="bibr" rid="article-159967.r34">[34]</xref></p>
        <p>Nausea and Dizziness: These symptoms may occur, especially when quickly changing positions from lying down to sitting.<xref ref-type="bibr" rid="article-159967.r35">[35]</xref></p>
        <p>Vision Changes: Tadalafil can cause blurred vision or alterations in color vision. Although it is uncommon, non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden vision loss in one or both eyes, which can lead to permanent blindness.<xref ref-type="bibr" rid="article-159967.r36">[36]</xref></p>
        <p>Hearing Loss: Sudden decrease or loss of hearing, sometimes accompanied by ear ringing and dizziness, is a rare but severe side effect. This can lead to permanent hearing impairment.<xref ref-type="bibr" rid="article-159967.r37">[37]</xref></p>
        <p>Priapism: One of the most severe potential adverse effects, characterized by a prolonged, painful erection lasting more than 4 hours. Priapism induced by tadalafil requires immediate medical attention to prevent permanent injury to the penis.<xref ref-type="bibr" rid="article-159967.r38">[38]</xref></p>
        <p>Gastroesophageal Reflux Disease (GERD):&#x000a0;Tadalafil can cause worsening of acid reflux symptoms.<xref ref-type="bibr" rid="article-159967.r39">[39]</xref></p>
        <p>Rash and Hypersensitivity Reactions: Skin reactions, including rash and urticaria (hives), as well as more severe swelling of the lips, tongue, or throat, can cause respiratory distress if severe.<xref ref-type="bibr" rid="article-159967.r40">[40]</xref></p>
        <p>
<bold>Drug-Drug Interactions&#x000a0;</bold>
</p>
        <p>Guanylate Cyclase Stimulators: Tadalafil is contraindicated in patients with pulmonary hypertension who use guanylate cyclase stimulators, like riociguat. Similar to nitrates, this combination can cause severe hypotension.</p>
        <p>Other PDE5 Inhibitors: The concurrent use of other PDE5 inhibitors with tadalafil should be avoided.</p>
        <p>Alpha-blockers and Antihypertensives: Caution is necessary when tadalafil is used with &#x003b1;-blockers or other antihypertensive agents due to the risk of additive blood pressure-lowering effects.</p>
        <p>CYP3A4 Inhibitors and Inducers: As tadalafil is metabolized by CYP3A4 inhibitors (like ticagrelor, ketoconazole, itraconazole, and ritonavir) can increase tadalafil exposure, while CYP3A4 inducers (like rifampin) can decrease its effectiveness.</p>
        <p>Alcohol: Excessive alcohol consumption can increase the risk of orthostatic hypotension when combined with tadalafil.<xref ref-type="bibr" rid="article-159967.r41">[41]</xref></p>
      </sec>
      <sec id="article-159967.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following are significant contraindications to administering tadalafil.<xref ref-type="bibr" rid="article-159967.r42">[42]</xref><xref ref-type="bibr" rid="article-159967.r43">[43]</xref><xref ref-type="bibr" rid="article-159967.r44">[44]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Nitrates: Tadalafil should not be used in patients taking nitrates (such as nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate), commonly used to treat angina. The combination can lead to a significant drop in blood pressure, which can be life-threatening.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity Reactions: Tadalafil should be avoided&#x000a0;in patients with known hypersensitivity to the drug or any inactive ingredient, as stated in the FDA product labeling. This includes any allergic reactions or severe adverse responses experienced in the past.<xref ref-type="bibr" rid="article-159967.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Guanylate Cyclase Stimulators: Tadalafil is contraindicated in patients using guanylate cyclase stimulators, as mentioned above.</p>
          </list-item>
        </list>
        <p>
<bold>Precautions</bold>
</p>
        <p>Severe Cardiovascular Conditions: Tadalafil should be avoided in individuals with a history of severe cardiovascular conditions, such as recent myocardial infarction (within the past 90 days), unstable angina, uncontrolled arrhythmias, or heart failure.</p>
        <p>Severe Hepatic Impairment: In patients with severe hepatic impairment, the use of tadalafil is&#x000a0;not recommended due to the increased risk of adverse reactions as the drug is metabolized in the liver.</p>
        <p>Retinitis Pigmentosa: Due to limited data on safety in this population, tadalafil should be used with caution in patients with retinitis pigmentosa, a genetic disorder affecting retinal PDE enzymes.</p>
        <p>Postural Hypotension and Antihypertensives: Caution is advised in patients with a predisposition to postural hypotension or those using antihypertensive medications, as tadalafil can amplify the blood pressure-lowering effects.</p>
        <p>Priapism: Tadalafil should be used cautiously in patients with conditions predisposing them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia) or in those with an anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease).</p>
        <p>In August 2023, the Food and Drug Administration advised consumers against buying or using Round 2, a product advertised and marketed as an energy, endurance, and strength booster, on different websites. FDA laboratory examination has established that Round 2&#x000a0;contains tadalafil.</p>
      </sec>
      <sec id="article-159967.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Tadalafil is known for its broad therapeutic index and offers a substantial margin of safety between its effective dose and the dose at which adverse effects occur. However, despite this relatively high safety margin, careful monitoring is crucial to ensure patient safety, optimize therapeutic outcomes, and minimize the risk of adverse effects. This monitoring involves a comprehensive assessment of the efficacy and safety aspects, including vigilant observation for signs of severe adverse reactions and managing potential drug interactions. Regular follow-up and patient education are integral to this process, emphasizing the importance of understanding when to seek medical help.</p>
        <p>When administering tadalafil, it is crucial to closely monitor the cardiovascular status of patients due to the drug's effect on&#x000a0;blood pressure. Regular monitoring of blood pressure is recommended, particularly for those on antihypertensive medications, as tadalafil can&#x000a0;enhance the blood pressure-lowering effects of these medications.<xref ref-type="bibr" rid="article-159967.r45">[45]</xref> Immediate reporting of changes in vision or hearing, such as sudden loss or decrease, is important as these could signify serious adverse effects. The occurrence of priapism, a prolonged erection, requires awareness and prompt medical attention. Monitoring is also vital for patients with significant hepatic or renal impairment, considering the metabolism and excretion pathways of tadalafil. It is important to be vigilant for signs of hypersensitivity reactions, including rash, hives, and swelling, especially of the lips, tongue, or throat. Continuous monitoring for potential drug interactions is essential, particularly with drugs affecting CYP3A4, nitrates, and &#x003b1;-blockers.<xref ref-type="bibr" rid="article-159967.r46">[46]</xref> Assessing tadalafil's efficacy in treating erectile dysfunction or benign prostatic hyperplasia symptoms is crucial in&#x000a0;determining the therapeutic approach. A&#x000a0;periodic evaluation of patient tolerance, focusing on side effects like headache, back pain, and dyspepsia, is important for maintaining quality of life during treatment.</p>
      </sec>
      <sec id="article-159967.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>In cases of tadalafil overdose, which can exacerbate common adverse effects like hypotension, headache, dizziness, and, in rare instances, priapism. There is no specific antidote for tadalafil.<xref ref-type="bibr" rid="article-159967.r47">[47]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The treatment approach is primarily supportive care to manage symptoms, emphasizing the importance of immediate medical intervention. Management typically includes gastrointestinal decontamination, especially if the overdose is recent, with measures like activated charcoal to absorb the drug. Symptomatic treatment for hypotension might involve fluid resuscitation or vasopressors, while discomforts such as headache and dizziness are managed with standard care. Priapism, a severe condition characterized by prolonged erection, requires urgent medical attention, often involving aspiration of blood from the corpus cavernosum or administration of sympathomimetic medications. Supportive care, including monitoring vital signs, fluid balance, and electrolytes, ensuring adequate hydration, and providing oxygen or ventilation support if needed, is crucial in managing tadalafil overdose.<xref ref-type="bibr" rid="article-159967.r48">[48]</xref></p>
      </sec>
      <sec id="article-159967.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tadalafil is an effective treatment choice for conditions such as erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. Tadalafil is effective in maintaining erectile function, alleviating BPH symptoms, and improving exercise capacity in PAH. Its long half-life of about 17.5 hours offers dosing flexibility, an advantage for patient compliance. For healthcare professionals, including physicians, urologists, cardiologists, pharmacists, and nurse practitioners, a thorough understanding of tadalafil's uses, limitations, and potential side effects is essential when a patient is prescribed this agent for any of the FDA-approved indications and off-labeled uses<bold>. </bold>This understanding is crucial given the drug's impact on blood pressure and possible interactions with other medications. Close monitoring for changes in cardiovascular status, signs of prolonged erection, and abrupt vision or hearing loss is imperative.</p>
        <p>Successful tadalafil treatment relies on a cohesive interprofessional healthcare team. Clinicians such as MDs, DOs, NPs, and PAs are typically responsible for initiating therapy, considering the patient's health and other medications. Pharmacists contribute significantly by checking drug interactions, ensuring correct dosage, and educating patients on side effects and medication management. Pharmacists can play an essential role&#x000a0;in medication adherence, proper&#x000a0;explanation of administration, and monitoring of adverse drug reactions.<xref ref-type="bibr" rid="article-159967.r49">[49]</xref> In situations involving adverse reactions or complications, the entire healthcare team, including emergency physicians, must be equipped to stabilize the patient, addressing any critical side effects or cardiovascular issues. Collaboration with specialists, like cardiologists or urologists, is crucial in such cases, often requiring vigilant monitoring.<xref ref-type="bibr" rid="article-159967.r50">[50]</xref>&#x000a0;This collaborative interprofessional approach significantly enhances patient outcomes, ensuring efficient management of the conditions treated with tadalafil. Clinical evidence supports this team-based care strategy, highlighting its importance in optimizing treatment efficacy, reducing adverse effects, and handling complications associated with tadalafil therapy.</p>
      </sec>
      <sec id="article-159967.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159967">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159967/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159967">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159967.s10">
        <title>References</title>
        <ref id="article-159967.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Nehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Breau</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Faraday</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sadeghi-Nejad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seftel</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Erectile Dysfunction: AUA Guideline.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>200</volume>
            <issue>3</issue>
            <fpage>633</fpage>
            <page-range>633-641</page-range>
            <pub-id pub-id-type="pmid">29746858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miernik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gratzke</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current Treatment for Benign Prostatic Hyperplasia.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2020</year>
            <month>Dec</month>
            <day>04</day>
            <volume>117</volume>
            <issue>49</issue>
            <fpage>843</fpage>
            <page-range>843-854</page-range>
            <pub-id pub-id-type="pmid">33593479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective.</article-title>
            <source>Int J Impot Res</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">30258189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Washington</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2010</year>
            <month>Sep</month>
            <day>07</day>
            <volume>4</volume>
            <fpage>159</fpage>
            <page-range>159-71</page-range>
            <pub-id pub-id-type="pmid">20856843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f3;nica</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>De Nucci</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil for the treatment of benign prostatic hyperplasia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>929</fpage>
            <page-range>929-937</page-range>
            <pub-id pub-id-type="pmid">30901259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warde</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Therapy: two birds, one stone: tadalafil is an effective treatment for men with both BPH-LUTS and ED.</article-title>
            <source>Nat Rev Urol</source>
            <year>2011</year>
            <month>Nov</month>
            <day>15</day>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>643</fpage>
            <pub-id pub-id-type="pmid">22083242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klinger</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil for the treatment of pulmonary arterial hypertension.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-28</page-range>
            <pub-id pub-id-type="pmid">21702653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klinger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bossone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duvall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fagan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frantsve-Hawley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Sederstrom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-586</page-range>
            <pub-id pub-id-type="pmid">30660783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langan</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Men's Health: Benign Prostatic Hyperplasia.</article-title>
            <source>FP Essent</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>503</volume>
            <fpage>18</fpage>
            <page-range>18-22</page-range>
            <pub-id pub-id-type="pmid">33856179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Codina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kazem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis.</article-title>
            <source>Clin Rheumatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>963</fpage>
            <page-range>963-965</page-range>
            <pub-id pub-id-type="pmid">32016657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pennardt</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High-altitude pulmonary edema: diagnosis, prevention, and treatment.</article-title>
            <source>Curr Sports Med Rep</source>
            <year>2013</year>
            <season>Mar-Apr</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-9</page-range>
            <pub-id pub-id-type="pmid">23478563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aldashev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and treatment of high-altitude pulmonary vascular disease.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Feb</month>
            <day>10</day>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>582</fpage>
            <page-range>582-90</page-range>
            <pub-id pub-id-type="pmid">25666980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.</article-title>
            <source>Pharmacol Rev</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>811</fpage>
            <page-range>811-59</page-range>
            <pub-id pub-id-type="pmid">21880989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arif</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.</article-title>
            <source>Clin Ther</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>993</fpage>
            <page-range>993-1004</page-range>
            <pub-id pub-id-type="pmid">21762988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forgue</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Bedding</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wrishko</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil pharmacokinetics in healthy subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-8</page-range>
            <pub-id pub-id-type="pmid">16487221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil.</article-title>
            <source>Drugs</source>
            <year>2003</year>
            <volume>63</volume>
            <issue>20</issue>
            <fpage>2203</fpage>
            <page-range>2203-12; discussion 2213-4</page-range>
            <pub-id pub-id-type="pmid">14498756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Troc&#x000f3;niz</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Tillmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Staab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rapado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forgue</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil population pharmacokinetics in patients with erectile dysfunction.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-90</page-range>
            <pub-id pub-id-type="pmid">17431603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2022</year>
            <month>Sep</month>
            <day>05</day>
            <volume>64</volume>
            <issue>1658</issue>
            <fpage>e1</fpage>
            <page-range>e1-e2</page-range>
            <pub-id pub-id-type="pmid">36094555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Tadalafil</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>8</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">31643246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatzimouratidis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.</article-title>
            <source>Ther Adv Urol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>135</fpage>
            <page-range>135-47</page-range>
            <pub-id pub-id-type="pmid">25083163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villapalos-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zubiaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mari&#x000e1;n-Revilla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soria-Chacartegui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Navares-G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Abril</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Lopez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Iglesias</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-V&#x000ed;lchez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abad-Santos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride.</article-title>
            <source>J Pers Med</source>
            <year>2023</year>
            <month>Oct</month>
            <day>31</day>
            <volume>13</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">38003881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beardsworth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frumkin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group</collab>
            </person-group>
            <article-title>Tadalafil therapy for pulmonary arterial hypertension.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Jun</month>
            <day>09</day>
            <volume>119</volume>
            <issue>22</issue>
            <fpage>2894</fpage>
            <page-range>2894-903</page-range>
            <pub-id pub-id-type="pmid">19470885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forgue</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bedding</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wrishko</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-35</page-range>
            <pub-id pub-id-type="pmid">16869816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Beecken</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1254706</fpage>
            <pub-id pub-id-type="pmid">37876727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alston</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Redman</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sones</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>An Overview of Obesity, Cholesterol, and Systemic Inflammation in Preeclampsia.</article-title>
            <source>Nutrients</source>
            <year>2022</year>
            <month>May</month>
            <day>17</day>
            <volume>14</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">35631228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Tadalafil</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">32697464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>RMF</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>GMB</given-names>
              </name>
              <name>
                <surname>Baygani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <collab>LVHV Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study.</article-title>
            <source>Pulm Circ</source>
            <year>2021</year>
            <season>Jul-Sep</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>20458940211024955</fpage>
            <pub-id pub-id-type="pmid">34234945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharlip</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Shumaker</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Goldfischer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Natanegara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>716</fpage>
            <page-range>716-25</page-range>
            <pub-id pub-id-type="pmid">18304286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verheyden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meuleman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>J&#x000fc;nemann</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Moncada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Valiquette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Casab&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Denne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.</article-title>
            <source>Eur Urol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>339</fpage>
            <page-range>339-44; discussion 344-5</page-range>
            <pub-id pub-id-type="pmid">15036680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brock</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Costigan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Anglin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>168</volume>
            <issue>4 Pt 1</issue>
            <fpage>1332</fpage>
            <page-range>1332-6</page-range>
            <pub-id pub-id-type="pmid">12352386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steers</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Pryor</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Natanegara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.</article-title>
            <source>J Sex Med</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>166</fpage>
            <page-range>166-175</page-range>
            <pub-id pub-id-type="pmid">17233782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Dec</month>
            <day>26</day>
            <volume>96</volume>
            <issue>12B</issue>
            <fpage>42M</fpage>
            <page-range>42M-46M</page-range>
            <pub-id pub-id-type="pmid">16387566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMahon</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction.</article-title>
            <source>J Sex Med</source>
            <year>2005</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-25; discussion 425-7</page-range>
            <pub-id pub-id-type="pmid">16422874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frajese</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Pozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frajese</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.</article-title>
            <source>Clin Interv Aging</source>
            <year>2006</year>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-49</page-range>
            <pub-id pub-id-type="pmid">18046921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafiee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bahri</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Teymouri Athar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Afsharrezaei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gholami</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.</article-title>
            <source>BMC Gastroenterol</source>
            <year>2023</year>
            <month>May</month>
            <day>22</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <pub-id pub-id-type="pmid">37217851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barroso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2021</year>
            <season>Apr-Jun</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>248</fpage>
            <page-range>248-259</page-range>
            <pub-id pub-id-type="pmid">34055262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wester</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ishiyama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karnezis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishiyama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sudden hearing loss after cialis (tadalafil) use: A unique case of cochlear hydrops.</article-title>
            <source>Laryngoscope</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>11</issue>
            <fpage>2615</fpage>
            <page-range>2615-2618</page-range>
            <pub-id pub-id-type="pmid">30208203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Harraz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of priapism: 2009 update.</article-title>
            <source>Nat Rev Urol</source>
            <year>2009</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>262</fpage>
            <page-range>262-71</page-range>
            <pub-id pub-id-type="pmid">19424174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donatucci</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Goldfischer</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Pommerville</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Elion-Mboussa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Viktrup</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.</article-title>
            <source>BJU Int</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>107</volume>
            <issue>7</issue>
            <fpage>1110</fpage>
            <page-range>1110-6</page-range>
            <pub-id pub-id-type="pmid">21244606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhanja</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Non pigmenting mucosal fixed drug eruption due to tadalafil: A report of two cases.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-9</page-range>
            <pub-id pub-id-type="pmid">24860753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>658</fpage>
            <pub-id pub-id-type="pmid">32457631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Padda</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Tripp</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Phosphodiesterase Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32644702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emmick</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of tadalafil.</article-title>
            <source>Am J Cardiol</source>
            <year>2003</year>
            <month>Nov</month>
            <day>06</day>
            <volume>92</volume>
            <issue>9A</issue>
            <fpage>37M</fpage>
            <page-range>37M-46M</page-range>
            <pub-id pub-id-type="pmid">14609622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aus&#x000f3;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Vicente</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Esquiva</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Visual Side Effects Linked to Sildenafil Consumption: An Update.</article-title>
            <source>Biomedicines</source>
            <year>2021</year>
            <month>Mar</month>
            <day>12</day>
            <volume>9</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">33809319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-7</page-range>
            <pub-id pub-id-type="pmid">16934043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ring</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Vandenbranden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bedding</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Forgue</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Eckstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wrighton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-75</page-range>
            <pub-id pub-id-type="pmid">15637532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMahon</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Florio</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction.</article-title>
            <source>J Sex Med</source>
            <year>2006</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>504</fpage>
            <page-range>504-11</page-range>
            <pub-id pub-id-type="pmid">16681476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Sharlip</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Becher</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.</article-title>
            <source>Sex Med Rev</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-252</page-range>
            <pub-id pub-id-type="pmid">28923561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zona</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Brittle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>How can pharmacists better support patients with chronic diseases? The patient perspective.</article-title>
            <source>J Am Pharm Assoc (2003)</source>
            <year>2023</year>
            <season>Nov-Dec</season>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>1776</fpage>
            <page-range>1776-1784.e3</page-range>
            <pub-id pub-id-type="pmid">37696490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159967.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutter</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Role of the cardiologist: clinical aspects of managing erectile dysfunction.</article-title>
            <source>Clin Cardiol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4 Suppl 1</issue>
            <fpage>I3</fpage>
            <page-range>I3-7</page-range>
            <pub-id pub-id-type="pmid">15115189</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
